XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company. The Company is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, for the treatment of multiple myeloma (MM), schizophrenia and Hepatitis C. the Company operates in two business: Drug Development and Medical Device. Also, through InterCure, it researches, develops, markets and sells home therapeutic devices for non-medicinal and non-invasive treatment of various diseases such as hypertension, heart failure, sleeplessness and mental stress. Its compound is Recombinant Human Erythropoietin (rHuEPO), a known compound that it is planning to develop for the prolongation of MM patients� survival and improvement of their quality of life. SAM-101 is a combination of anti-psychotic drugs with minocycline, a recognized medicinal compound, for the treatment of schizophrenia.